Extent and Clinical Consequences of Antibody Formation Against Adalimumab in Patients With Plaque Psoriasis
Extent and Clinical Consequences of Antibody Formation Against Adalimumab in Patients With Plaque Psoriasis
复制标题
DOI：
10.1001/archdermatol.2009.347
复制
发表时间：
2010-02-01
影响因子：
--
通讯作者：
Wolbink, Gert-Jan
中科院分区：
文献类型：
--
作者：
Lecluse, Lidian L. A.;Driessen, Rieke J. B.;Wolbink, Gert-Jan
目的：研究斑块状银屑病患者中阿达木单抗抗体形成的程度以及这些抗体是否具有临床后果。同时，研究阿达木单抗抗体和阿达木单抗谷滴度之间的关系。设计：前瞻性观察性队列研究。设定：患者：所有开始阿达木单抗治疗慢性斑块状银屑病的连续患者。干预：阿达木单抗治疗（根据标签）。主要结果测量：阿达木单抗抗体滴度，阿达木单抗谷浓度，以及第12周和第24周的银屑病面积和严重程度指数。结果：在24周的治疗期间，29例患者中有13例（45%）检测到阿达木单抗抗体。在第12周和第24周，阿达木单抗抗体滴度低、高和无患者的应答率差异有统计学意义（P= 0.04和P
Objectives: To investigate the extent antibodies to adalimumab are formed in patients with plaque psoriasis and whether these antibodies have clinical consequences. Also, to examine the relationship between antibodies to adalimumab and adalimumab trough titers.Design: Prospective observational cohort study. Setting: Two Dutch dermatology departments in university hospitals.Patients: All consecutive patients starting a regimen of adalimumab for chronic plaque psoriasis. Patients were screened and fulfilled the Dutch reimbursement criteria for adalimumab to treat psoriasis.Intervention: Adalimumab treatment (per label).Main Outcome Measures: The titer of antibodies to adalimumab, the adalimumab trough concentration, and the Psoriasis Area and Severity Index at weeks 12 and 24.Results: Antibodies to adalimumab were detected in 13 of 29 patients (45%) during 24 weeks of treatment. Differences in response rates among patients with low, high, and no titers of antibodies to adalimumab were significant at weeks 12 and 24 (P=.04 and P